Keywords
animal models
atidepressants
Abstract
In today's world, depression is one of the more prevalent forms of mental illness. According to WHO, about 10%-30% of all women and 7%-15% of all men are afflicted by depression at least once in their life-times. Today, depression is assessed to be affecting 350 million people. Regarding this issue, an important challenge for current psychopharmacology is to develop new, more effective pharmacotherapy and to understand the mechanism of action of known antidepressants. Furthermore, there is the necessity to improve the effectiveness of anti-depression treatment by way of bringing about an understanding of the neurobiology of this illness. In achieving these objectives, animal models of depression can be useful. Yet, presently, all available animal models of depression rely on two principles: the actions of known antidepressants or the responses to stress. In this paper, we present an overview of the most widely used animal tests and models that are employed in assessing antidepressant-like activity in rodents. These include amphetamine potentiation, reversal of reserpine action, the forced swimming test, the tail suspension test, learned helplessness, chronic mild stress and social defeat stress. Moreover, the advantages and major drawbacks of each model are also discussed.References
1. Abelaira H.M., Réus G.Z., Quevedo J.: Animal models as tools to study the pathophysiology of depression. Revista Brasileira de Psiquiatria, 35, 2013
2. Avgustinovich D.F., Kovalenko I.L., Kudryavtseva N.N.: A model of anxious depression: persistence of behavioral pathology. Neuroscience and Behavioral Physiology, 35, 917–924, 2005
3. Berton O. et al.: Essential role of BDNF in mesolimbic dopamine pathway in social defeat stress. Science, 311, 864-868, 2006
4. Brown G.W., Prudo R.: Psychiatric disorder in a rural and an urban population: Ethology of depression. Psychological Medicine, 11, 581-599, 1981
5. Coppen A.: The biochemistry of affective disorder. British Journal of Psychiatry, 7, 113, 1237-1264, 1967
6. Costa E., Garattini S., Valzelli L.: Interactions between reserpine, chlorpromazine and imipramine. Experientia, 16, 461-463, 1960
7. Dall’olio R. et al.: Behavioral differentiation between pharmacokinetic and pharmacodynamics components of the interaction of antidepressants or neuroleptics with methamphetamine. Psychopharmacology, 90, 18-23, 1986 [CrossRef]
8. Everett G.M.: The DOPA response potentiation test and its use in screening for antidepressant drugs. Excerpta Medica, 6, 164-167, 1971
9. Fava M., Kendler K.S.: Major depressive disorder. Neuron, 28, 335-341, 2000
10. Halliwell G., Qunton R.M., Williams F.E.: A comparison of imipramine, chloropromazine and related drugs in various test involving autonomic functions and antagonism of reserpine. Br. J. Pharmacol., 23, 330-350, 1964
11. Holsboer F.: Antidepressant drug discovery in the postgenomic era. World J. Biol. Psychiatry, 2, 165–177, 2001
12. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology, 23, 477–501, 2001
13. Hua-Cheng YAN et al.: Behavioral animal models of depression. Neuroscience Bulletin, 26, 327-337, 2010
14. Huhman K.L.: Social conflict models: Can they inform us about human psychopathology? Horm. Behav., 50, 640-646, 2006
15. Katz R.J., Roth K.A., Carroll B.J.: Acute and chronic stress effects on open field activity in the rat: implications for a model of depression. Neuroscience and Biobehavioral Reviews, 5, 247-251, 1981
16. Krishnan V. et al.: Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell, 131, 391-404, 2007
17. Kudryavtseva N.N., Bakshtanovskaya I.V., Koryakina L.A.: Social model of depression in mice of C57BL/6J strain. Pharmacol. Biochem. Behav., 38, 315-320, 1991
18. Lazure K. et al.: Association between depression and survival or disease recurrence in patients with head and neck cancer enrolled in a depression prevention trial. Head Neck-Journal for Sciences Specialties Head Neck, 31, 888-892, 2009
19. Litwack G. (2010). Models of depression. In: Hormones of the limbic system. Duman C.H., p.1-15
20. McKenna M.T et al.: Assessing the burden of disease in the United States using disability-adjusted life years. Journal of Preventive Medicine, 28, 415-423, 2005
21. Musselman D.L., Evans D.L., Nemeroff C.B.: The relationship of depression to cardiovascular disease, epidemiology, biology, and treatment. Archives of General Psychiatry, 55, 580-592, 1998
22. Nestler J. E. et al.: Neurobiology of depression. Neuron, 34, 13-35, 2002
23. Neu P.: Correlation of depression with stroke. Pathophysiological mechanisms. Nervenarzt, 80, 772, 2009
24. Papp M., Moryl E., Wilner P.: Pharmacological validation of the chronic mild stress model of depression. Eur. J. Pharmacol., 296, 129-136, 1996
25. Páez-Pereda M.: New drug targets in the signalling pathways activated by antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 29, 1010-1016, 2005
26. Petit-Demouliere B., Chenu F., Bourin M.: Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology, 177, 245-255, 2005
27. Peyrot, M.: Depression: a quiet killer by any name. Diabetes Care, 26, 2952-2953, 2003
28. Popik P.: Metodyka przedklinicznych badań nad depresją i lekami przeciwdepresyjnymi. Depresja i leki przeciwdepresyjne – 10 lat później. Przewłocka B (red.), XIII Zimowa Szkoła Instytutu Farmakologii PAN, 27-44, 1996
29. Porsolt R.D. et al.: Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol., 47, 379-91, 1978
30. Porsolt R.D., Bertin A., Jalfre M.: Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther., 36, 229-327, 1977
31. Porsol R.D., Bertin A. Jalfre M.: Behavioral despair in mice: A primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther., 229(2), 327–336, 1977
32. Porsolt R.D. Le Pichon M. Jalfre M.: Depression: A new animal model sensitive to antidepressant treatments. Nature, 266(5604), 730–732, 1977
33. Porsolt R.D., Bertin A. Jalfre M.:‘‘Behavioural despair’’ in rats and mice: Strain differences and the effects of imipramine. Eur. J. Pharmacol., 51(3), 291–294, 1978
34. Pothion S. et al.: Strain differences in sucrose preference and in the consequences of unpredictable chronic mild stress. Behav. Brain. Res., 155, 135-146, 2004
35. Sapolsky R.M.: Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch. Gen. Psychiatry, 57, 925–935, 2000
36. Schildkraut J.J.: The catecholamine hypothesis of affective disorder: a review of supporting evidence. American Journal of Psychiatry, 122, 1032-1039, 1965
37. Seligman M.E.P., Maier S.F., Peterson Ch. (1995), Learned Helplessness. A Theory for the Age of Personal Control.
38. Stemmelin J, et al.: Implication of beta3-adrenoceptors in the antidepressant-like effects of amibegron using Adrb3 knockout mice in the chronic mild stress. Behav. Brain Res., 206, 310-312, 2010
39. Steru L. et al.: Tail suspension test: A new method for screening antidepressants in mice. Psychopharmacology, 85, 367–370, 1985
40. Vaishnav K., Nestler E. J. (2013). Animal Models of Depression: Molecular Perspectives. In: Molecular and Functional Models in Neuropsychiatry. Hagan J. J. (editor) p.121-148
41. Willner P. (1991). Behavioural models in psychofarmacology. Theoretical, industrial and clinical perspectives. p.91-113
42. Willner P., Mitchell P.J.: The validity of animal models of predisposition to depression. Behav Pharmacol., 13, 169-188, 2002
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2016 Authors